Volver

Organon & Co

Ticker: OGN ISIN: US68622V1061
Añadir al portafolio Análisis de cartera en 2min
Stock Mid-cap Dividend payer
Capitalización
3,84 MM $
P/E
2,95
Forward P/E
5,03
Profit margin
20,30%
Revenue growth QoQ
4,10%
Div. yield
7,51%
Beta
0,80
13,75 $ 0,00%
Precio a fecha de 2026-08-25 · NYSE

Rendimiento por período

Rendimientos acumulados
1 Month +1,70%
6 Months +83,63%
1 Year +52,83%
5 Years -13,33% p.a.-51,07%
Since inception -12,03% p.a.-49,18%
Rendimientos por año
YTD +92,81%
2025 -50,71%
2024 +9,92%
2023 -45,12%
2022 -4,86%

Key stats

Market cap
3,84 MM
P/E
2,95
Dividend yield
7,51%
Beta
0,80
52-week range
12.85 - 22.70
50-day MA
15,84
200-day MA
18,94
Section 1

Business overview

Company profile data from fundamentals.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 0,00%
ROA 7,91%
Profit margin 20,30%
Operating margin 24,65%
Revenue/share TTM 24,98
Revenue TTM 6,41 MM
EBITDA 1,76 MM
Gross profit TTM 3,89 MM
Beta 0,80

Valuation

Trailing P/E 2,95
Forward P/E 5,03
P/B 7,79
P/S 0,60
EV/EBITDA 7,59
EV/Revenue 1,85
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 4,14
Quarterly earnings growth 5,08%
Revenue TTM 6,41 MM
Reported quarters 18
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 7,51%
Forward annual div. yield 7,51%
Dividend per share 1,1200
Payout ratio 27,38%
Ex-dividend date 2024-11-12
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 29,29 $
Analyst rating 3.3333

Ownership & short interest

Shares outstanding 257,54 M
Shares float 256,70 M
Institutional ownership 81,64%
Insider ownership 17,70%
Short ratio 5,42
Short % of float 7,91%

Details

Instrument metadata and source update timestamps.

Symbol OGN
Name Organon & Co
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US68622V1061
Country USA
Code + exchange OGN.NYSE
Last price date 2024-12-31
Fundamentals updated 2025-01-01

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.